Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Raising the Bar for Patients with HR+/HER2- Early Breast Cancer

ESMO-Webinar-Breast-Cancer-1000x250
Live on
25 May 2022 at 18:30 CEST

It is with great pleasure that I invite you to participate in a new ESMO webinar on management of patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative early breast cancer.

This webinar is developed with the aim to provide an overview on risk assessment and rational application of adjuvant strategies in patients with early luminal HER2-negative breast cancer, on the value of CDK4/6 inhibitors in the adjuvant management of these patients, as well as to highlight ongoing research in this field.

We will begin with a lecture on clinicopathologic and molecular tools for assessing risk when managing patients with HR-positive, HER2-negative early breast cancer. This will be followed by updated data in terms of clinical results and implications for practice of the latest evidence from CDK4/6 inhibitors trials in the management of these patients. Finally, there will be multidisciplinary team presentation of two clinical cases that will highlight efficacy, safety, and patient communication aspects, followed by discussion with the audience.

The programme is designed to provide an overview of the current evidence, offer expert opinion exchange, interaction with audience and provide some important considerations regarding multidisciplinary assessment and management of patients with HR-positive, HER-negative early breast cancer in the personalised medicine era. I strongly encourage and invite you to register and join us all in this ESMO activity.

Prof. Dr. med. Sibylle Loibl

Chair and CEO, German Breast Group, Neu-Isenburg, Germany
Goethe University, Frankfurt, Germany
Bethanien Centre for Haematology and Oncology, Frankfurt, Germany

Speakers

Programme

Time

Title

Speaker

5 min

Welcome and Introduction

Sibylle Loibl

15 min

Clinicopathologic and molecular tools for assessing risk when managing patients with HR+/HER2- early breast cancer

Evandro de Azambuja

15 min

Updates and clinical implications of the latest evidence on CDK4/6 inhibitors

Stephen Johnston

15 min

MDT presentation of 2 clinical cases, highlighting efficacy, safety, patient communication aspects

Shaheenah Dawood

15 min

Discussion of the 2 clinical cases and live Q&A

All

A certificate of attendance and 1 ESMO MORA category point will be awarded for live attendance to this event

Learning objectives:

  • To increase knowledge on risk assessment and rational application of adjuvant strategies in patients with early luminal HER2- breast cancer
  • To provide up to date information on the value of CDK4/6 inhibitors in adjuvant management of these patients as well as highlight ongoing research
  • To emphasise the value of multidisciplinary assessment of patients with early breast cancer in the personalised medicine era

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.